Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist
Abstract Eph receptors have emerged as targets for therapy in both neoplastic and non-neoplastic disease, however, particularly in non-neoplastic diseases, redundancy of function limits the effectiveness of targeting individual Eph proteins. We have shown previously that a soluble fusion protein, wh...
Guardado en:
Autores principales: | Cassandra L. Pegg, Leanne T. Cooper, Jing Zhao, Michael Gerometta, Fiona M. Smith, Michael Yeh, Perry F. Bartlett, Jeffrey J. Gorman, Andrew W. Boyd |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8eef0bce7cd74492b8bf629ada41ee50 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Shuo Gu, et al.
Publicado: (2018) -
Molecular basis of EphA2 recognition by gHgL from gammaherpesviruses
por: Chao Su, et al.
Publicado: (2020) -
Glucose homeostasis is regulated by pancreatic β-cell cilia via endosomal EphA-processing
por: Francesco Volta, et al.
Publicado: (2019) -
Regulation of the EphA2 receptor intracellular region by phosphomimetic negative charges in the kinase-SAM linker
por: Bernhard C. Lechtenberg, et al.
Publicado: (2021) -
Role of microRNA-26b in glioma development and its mediated regulation on EphA2.
por: Ning Wu, et al.
Publicado: (2011)